Pα+ Psychedelic Bulletin #231: Compass Shares 52 Week Follow-Up, Training Grant Recipients; Xylo Enters the Clinic; RFK Jr. Hosts Hubbard

Compass Shares 52-Week Follow-Up and Five Training Grant Recipients

Earlier this month, Compass Pathways shared topline data from Part C of its smaller, placebo-controlled Phase 3 trial, COMP005.

As a reminder, COMP005 enrolled 258 patients with treatment-resistant depression (TRD) to receive either a 25 mg dose of the company’s psilocybin candidate (COMP360) or inert placebo. Participants received their first dose in Part A, a 6-week blinded portion of the study, before potentially being retreated with the same dose in Part B, a further 20-week blinded segment. Part C, then, is the 26-week open-label element of the trial, in which participants who relapsed or did not remit in Part B were offered a 25 mg dose of psilocybin. Approximately 70% (179/258) of study participants entered Part C, Compass says, with a roughly equal dropout rate in both groups, though the precise reasons for discontinuations have not been disclosed.

The headline is that Compass observed “[n]otable additional benefit” of a further dose in Part C, “leading to an average 13-point reduction from baseline at Week 52”, in terms of MADRS scores among those who received the active dose in Part A.

It further reports response and remission rates for the combination of participants from the 25 mg and placebo arms who received the ...